As of Mar 27
| +6.13 / +1.37%|
The 23 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals have a median target of 450.00, with a high estimate of 560.00 and a low estimate of 375.00. The median estimate represents a -0.99% decrease from the last price of 454.50.
The current consensus among 25 polled investment analysts is to Buy stock in Regeneron Pharmaceuticals. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.